Our mission is to bring hope and life-changing therapies to patients and their families affected by rare diseases, and our primary focus is Duchenne muscular dystrophy.
Location: United States, Massachusetts, Cambridge
Member count: 11-50
Total raised: $52.8M
Founded date: 2008
Investors 3
Funding Rounds 2
Date | Series | Amount | Investors | Deal News |
31.03.2015 | - | $20.4M | - | medcitynew... |
15.11.2013 | Series B | $32.4M | - | finsmes.co... |
Mentions in press and media 12
Date | Title | Description | Category | Author | Source |
16.04.2021 | CATABASIS ... | 2020 ANNUAL REPORT Dear Share... | - | - | marketscre... |
01.02.2021 | Catabasis ... | Catabasis Pharmaceuticals, Inc... | USA | - | finsmes.co... |
04.08.2020 | Catabasis ... | BOSTON--(BUSINESS WIRE)--Catab... | - | - | svhealthin... |
31.01.2017 | Catabasis... | Catabasis’ lead drug just flo... | - | John Carro... | endpts.com... |
29.06.2016 | The biotec... | There was a time after the 20... | Financing | John Carro... | endpts.com... |
31.03.2015 | Catabasis ... | The MIT Technology Review wrot... | - | - | medcitynew... |
01.05.2014 | Morgenthal... | Carusi said in a statement tha... | - | - | medcitynew... |
15.11.2013 | Catabasis ... | CAMBRIDGE, MA, Catabasis Pha... | - | - | vcnewsdail... |
15.11.2013 | Catabasis ... | Catabasis Pharmaceuticals, Inc... | funding U... | - | finsmes.co... |
06.02.2013 | Catabasis ... | Catabasis Pharmaceuticals has ... | Venture Ca... | - | fiercebiot... |
Show more